Expression and Regulation of Chemokines in Murine and Human Type 1 Diabetes
- Suparna A. Sarkar1,
- Catherine E. Lee1,
- Francisco Victorino1,2,
- Tom T. Nguyen1,
- Jay A. Walters1,
- Adam Burrack1,2,
- Jens Eberlein1,
- Steven K. Hildemann3 and
- Dirk Homann1,2,4⇓
- 1Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado
- 2Integrated Department of Immunology, University of Colorado Denver and National Jewish Health, Denver, Colorado
- 3Innere Medizin III, Unversitätsklinik Freiburg, Freiburg, Germany
- 4Department of Anesthesiology, University of Colorado Denver, Aurora, Colorado
- Corresponding author: Dirk Homann, .
More than one-half of the ~50 human chemokines have been associated with or implicated in the pathogenesis of type 1 diabetes, yet their actual expression patterns in the islet environment of type 1 diabetic patients remain, at present, poorly defined. Here, we have integrated a human islet culture system, murine models of virus-induced and spontaneous type 1 diabetes, and the histopathological examination of pancreata from diabetic organ donors with the goal of providing a foundation for the informed selection of potential therapeutic targets within the chemokine/receptor family. Chemokine (C-C motif) ligand (CCL) 5 (CCL5), CCL8, CCL22, chemokine (C-X-C motif) ligand (CXCL) 9 (CXCL9), CXCL10, and chemokine (C-X3-C motif) ligand (CX3CL) 1 (CX3CL1) were the major chemokines transcribed (in an inducible nitric oxide synthase–dependent but not nuclear factor-κB–dependent fashion) and translated by human islet cells in response to in vitro inflammatory stimuli. CXCL10 was identified as the dominant chemokine expressed in vivo in the islet environment of prediabetic animals and type 1 diabetic patients, whereas CCL5, CCL8, CXCL9, and CX3CL1 proteins were present at lower levels in the islets of both species. Of importance, additional expression of the same chemokines in human acinar tissues emphasizes an underappreciated involvement of the exocrine pancreas in the natural course of type 1 diabetes that will require consideration for additional type 1 diabetes pathogenesis and immune intervention studies.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0853/-/DC1.
- Received June 21, 2011.
- Accepted November 4, 2011.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.